Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunogenicity of Two Investigational Serogroup B Meningococcal Vaccines in the First Year of Life

15 Sept 2010

Abstract excerpt

BACKGROUND: An investigational vaccine against serogroup B meningococcal (MenB) disease containing 3 main recombinant proteins (factor H-binding protein, Neisserial adhesion A, and Neisserial heparin-binding antigen) has been developed. We evaluated the immunogenicity and reactogenicity of a 3-dose course of this vaccine administered alone (recombinant MenB [rMenB]) or combined with the outer membrane vesicle...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Infections and Vaccines
Share to Pneumonia and Respiratory Infections
Share to Virology and Viral Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20844462
DOI: 10.1097/inf.0b013e3181f59f6d

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity of Two Investigational Serogroup B Meningococcal Vaccines in the First Year of LifePMID 20844462Read ↗

The Development of a Vaccine Against Meningococcus B Using Reverse VaccinologySemantic proximity Read ↗

Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolatesSemantic proximity Read ↗

A Bivalent Meningococcal B Vaccine in Adolescents and Young AdultsSemantic proximity Read ↗

Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy AdolescentsSemantic proximity Read ↗

Use of expanded Neisseria meningitidis serogroup B panels with the serum bactericidal antibody assay for the evaluation of meningococcal B vaccine effectivenessSemantic proximity Read ↗

Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effectSemantic proximity Read ↗

Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigenSemantic proximity Read ↗

Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.Semantic proximity Read ↗

From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccineSemantic proximity Read ↗

BexseroSemantic proximity Read ↗

Meningococcal serogroup B vaccines: Estimating breadth of coverageSemantic proximity Read ↗

A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.